NASDAQ:CRONCronos Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cronos Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.69 +0.23 (+3.56 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$6.32Now: $6.69▼$6.9150-Day Range$4.84MA: $5.98▼$6.7452-Week Range$4.00Now: $6.69▼$17.86Volume7.56 million shsAverage Volume7.70 million shsMarket Capitalization$2.33 billionP/E Ratio7.27Dividend YieldN/ABeta1.91 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.44, Cronos Group has a potential upside of 41.2% from its current price of $6.69.Amount of Analyst CoverageCronos Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesCronos Group has received 428 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCronos Group has received 505 “underperform” votes. (Add your “underperform” vote.)Community SentimentCronos Group has received 54.13% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote “Outperform” if you believe CRON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.93% of the stock of Cronos Group is held by insiders.Percentage Held by InstitutionsOnly 13.70% of the stock of Cronos Group is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cronos Group are expected to decrease in the coming year, from ($0.13) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is 7.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is 7.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.59.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRON Previous Symbol CUSIPN/A CIKN/A Webwww.thecronosgroup.com Phone416-504-0004Debt Debt-to-Equity Ratio0.01 Current Ratio6.97 Quick Ratio6.75Price-To-Earnings Trailing P/E Ratio7.27 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.64 million Price / Sales91.01 Cash Flow$0.77 per share Price / Cash Flow8.68 Book Value$5.01 per share Price / Book1.34Profitability EPS (Most Recent Fiscal Year)$0.67 Net Income$1.17 billion Net Margins2,705.97% Return on Equity0.72% Return on Assets0.53%Miscellaneous Employees291 Outstanding Shares348,817,000Market Cap$2.33 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:CRON Rates by TradingView Receive CRON News and Ratings via Email Sign-up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Cronos Group (NASDAQ:CRON) Frequently Asked Questions How has Cronos Group's stock been impacted by COVID-19 (Coronavirus)? Cronos Group's stock was trading at $5.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRON shares have increased by 23.7% and is now trading at $6.69. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cronos Group? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cronos Group. When is Cronos Group's next earnings date? Cronos Group is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cronos Group. How were Cronos Group's earnings last quarter? Cronos Group Inc (NASDAQ:CRON) posted its earnings results on Friday, May, 8th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27. The firm had revenue of $8.40 million for the quarter, compared to the consensus estimate of $13.05 million. Cronos Group had a net margin of 2,705.97% and a return on equity of 0.72%. Cronos Group's revenue was up 29.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.48 earnings per share. View Cronos Group's earnings history. What price target have analysts set for CRON? 11 Wall Street analysts have issued 1 year target prices for Cronos Group's shares. Their forecasts range from $6.50 to $17.00. On average, they expect Cronos Group's stock price to reach $9.44 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. View analysts' price targets for Cronos Group. Has Cronos Group been receiving favorable news coverage? Media coverage about CRON stock has been trending very negative on Thursday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cronos Group earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCronos Group. Are investors shorting Cronos Group? Cronos Group saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 42,590,000 shares, a decline of 11.4% from the April 15th total of 48,060,000 shares. Based on an average daily volume of 6,500,000 shares, the short-interest ratio is presently 6.6 days. Approximately 23.5% of the shares of the company are short sold. View Cronos Group's Current Options Chain. Who are some of Cronos Group's key competitors? Some companies that are related to Cronos Group include Canopy Growth (CGC), STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Tilray (TLRY), Aphria (APHA), Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and True Drinks (TRUU). View all competitors. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Tilray (TLRY), Aphria (APHA), NVIDIA (NVDA), Dollar Tree (DLTR), Advanced Micro Devices (AMD), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI). Who are Cronos Group's key executives? Cronos Group's management team includes the following people: Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)Mr. David Hsu, Chief Operating OfficerMs. Xiuming Shum, Gen. Counsel & Corp. Sec.Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.Mr. William Hilson, Chief Commercial Officer What is Cronos Group's stock symbol? Cronos Group trades on the NASDAQ under the ticker symbol "CRON." Who are Cronos Group's major shareholders? Cronos Group's stock is owned by many different institutional and retail investors. Top institutional investors include ETF Managers Group LLC (2.24%), Morgan Stanley (0.38%), Swiss National Bank (0.21%), Legal & General Group Plc (0.19%), Public Sector Pension Investment Board (0.16%) and Polar Asset Management Partners Inc. (0.14%). Which institutional investors are selling Cronos Group stock? CRON stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Polar Asset Management Partners Inc., Morgan Stanley, Wedbush Securities Inc., Janney Montgomery Scott LLC, Cambridge Investment Research Advisors Inc., Janus Henderson Group PLC, and HighTower Advisors LLC. Which institutional investors are buying Cronos Group stock? CRON stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Legal & General Group Plc, Valinor Management L.P., Nomura Holdings Inc., Geode Capital Management LLC, ETF Managers Group LLC, Swiss National Bank, and APG Asset Management N.V.. How do I buy shares of Cronos Group? Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cronos Group's stock price today? One share of CRON stock can currently be purchased for approximately $6.69. How big of a company is Cronos Group? Cronos Group has a market capitalization of $2.33 billion and generates $25.64 million in revenue each year. The company earns $1.17 billion in net income (profit) each year or $0.67 on an earnings per share basis. Cronos Group employs 291 workers across the globe. What is Cronos Group's official website? The official website for Cronos Group is www.thecronosgroup.com. How can I contact Cronos Group? Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 416-504-0004. This page was last updated on 6/4/2020 by MarketBeat.com Staff
